Search the Newsreel

Is Cullen/Frost Bankers (CFR) Undervalued On Raised 2026 Earnings Guidance?

LeMaitre Vascular (NASDAQ:LMAT) Sets New 1-Year Low on Analyst Downgrade

LeMaitre Vascular (NASDAQ:LMAT) shares hit a new 52-week low after Wells Fargo downgraded its price target and maintained an equal-weight rating, amidst a broader shift in analyst sentiment to "Hold." The company's Q2 revenue and EPS, despite year-over-year growth, missed analyst expectations, leading to …

LeMaitre Vascular, Inc. Stock 12‑Month Price Target Cut to $116.25, Implies 10% Upside

LeMaitre Vascular, Inc.'s average 12-month price target has been lowered from $118.75 to $116.25 by 8 analysts, suggesting a 10% upside from its Aug. 4 closing price. The consensus rating remains a "Buy" from 9 analysts, with 5 recommending Buy and 4 recommending Hold.

Cullinan Oncology earnings up next: Can pipeline justify cash burn?

Cullinan Therapeutics Inc. is set to report second-quarter earnings, with analysts expecting a wider loss per share. The pre-revenue biotech, with a $1.08 billion market cap, is advancing two late-stage oncology programs, CLN-049 and zipalertinib, which have garnered bullish Wall Street sentiment and significant …

Cullen/Frost Bankers’s Q2 Earnings Call: Our Top 5 Analyst Questions

Cullen/Frost Bankers (CFR) reported Q2 revenue below but non-GAAP profit above analyst expectations, driven by strong customer growth despite challenges in multifamily commercial real estate and increased lending competition. The article highlights key analyst questions from the earnings call, focusing on net interest income …

Cullen/Frost's Branch Expansion Is a Strong Driver for Earnings Growth

Cullen/Frost, a regional bank operating exclusively in Texas, has historically demonstrated resilience through various economic downturns, including energy crises and the coronavirus pandemic. The article highlights that the bank's ongoing branch expansion is a significant contributor to its earnings growth. This strategy, combined with …

Airsculpt Technologies Inc (AIRS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Airsculpt Technologies Inc (AIRS), detailing analyst ratings, price targets, and expected EPS and revenue figures. The current earnings forecast score for AIRS is 6.67, with an average price target of $6.50. Analysts currently have a "Hold" rating …

Federal Agricultural Mortgage (NYSE: AGM) nets 463 shares from SAR exercise

Brian M. Brinch, EVP and Chief Risk Officer of Federal Agricultural Mortgage (AGM), exercised 939 stock appreciation rights (SARs) granted in March 2022. Through net share settlement, he received 463 Class C shares, retaining 238 while 225 shares were withheld for tax obligations and …

LeMaitre Vascular stock hits 52-week low at 79.38 USD

LeMaitre Vascular (LMAT) stock recently hit a 52-week low at $79.38, despite having a strong 1-year return of nearly 25% and being up over 31% year-to-date. The medical device maker is trading below its Fair Value estimate, with analysts setting price targets between $100 …

4D Molecular Therapeutics, Inc. (FDMT) insider sells 26,842 shares under plan

David Kirn, a director and officer at 4D Molecular Therapeutics, Inc. (FDMT), sold 26,842 shares of common stock on August 4, 2026, at a weighted average price of $10.2301 per share. This transaction was conducted under a 10b5-1 trading plan established on January 9, …

Moleculin Biotech (MBRX) CSO buys common stock and Series I Warrants

Moleculin Biotech's Chief Science Officer, Donald H. Picker, recently purchased 173,333 shares of common stock and Series I Warrants to acquire an additional 519,999 shares. These transactions occurred on August 3, 2026, as part of a public offering at a combined price of $0.75 …

LeMaitre Vascular Down Over 22%, On Track for Largest Percent Decrease Since October 2008 -- Data Talk

LeMaitre Vascular Inc. (LMAT) experienced a significant drop of over 22%, trading at $82.06, which would mark its lowest close since January 2026. This decline puts the company on track for its largest percentage decrease since October 2008. The stock is down 30.1% from …

Earnings Preview: IMDX to Report Financial Results Post-market on August 10

This article announces that IMDX is scheduled to report its financial results after market close on August 10. The report will provide key insights into the company's performance, which investors and analysts will be watching closely.

LeMaitre Vascular (NASDAQ:LMAT) Price Target Cut to $94.00 by Analysts at Wells Fargo & Company

Wells Fargo & Company analysts have cut their price target for LeMaitre Vascular (NASDAQ:LMAT) to $94.00 from $104.00, maintaining an "equal weight" rating. This adjustment follows the company's recent earnings report where Q2 EPS of $0.74 missed the consensus estimate of $0.81, and revenue …

PB vs. CFR: Which Stock Should Value Investors Buy Now?

Investors interested in Banks - Southwest stocks are likely familiar with Prosperity Bancshares (PB) and Cullen/Frost Bankers (CFR). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We have …

LeMaitre Vascular (NASDAQ:LMAT) Shares Gap Down on Disappointing Earnings

Price to sales forward of Moleculin Biotech, Inc. – LS:A41SET

This article provides financial information for Moleculin Biotech, Inc. (A41SET) on the TradingView platform. It specifically highlights the "Price to sales forward" metric for the company, accessible through the Lang & Schwarz Tradecenter. The content itself is minimalist, primarily serving as a header for …

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces $0.25 Quarterly Dividend

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend of $0.25 per share, payable on September 3rd to shareholders of record on August 20th. This announcement comes despite the company missing analyst expectations for both Q2 revenue and EPS, and subsequently lowering its full-year 2026 …

LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Lowered by Barrington Research

Royal Bank of Canada Sells 18,448 Shares of LeMaitre Vascular, Inc. $LMAT

Royal Bank of Canada reduced its stake in LeMaitre Vascular, Inc. (LMAT) by 6.3% in the first quarter, selling 18,448 shares but still retaining a significant holding of 272,654 shares valued at $29.8 million. This comes as LeMaitre Vascular reported Q2 earnings that missed …

MOLECULAR PARTNERS AG (MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (MOLN)

Bernstein Liebhard LLP has issued a shareholder class action alert against Molecular Partners AG (MOLN), reminding investors of the upcoming September 12, 2022 deadline to file a lead plaintiff motion. The lawsuit, filed in the United States District Court for the Southern District of …

Agriculture & Natural Solutions Acquisition Corporation Revenue Breakdown – NASDAQ:ANSC

Earnings To Watch: Oculis Holding AG (OCS) Reports Q2 2026 Result

Clever Culture Doubles Big Pharma Customers as Its APAS Platform Gains Global Traction

Molecular Partners AG (MOLN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

China Partytime Schedules Board Meeting to Review Interim Results and Dividend

LeMaitre Vascular Inc (LMAT) (Q2 2026) Earnings Call Highlights: Strong EPS Growth and ...

This article first appeared on GuruFocus. Revenue: Q2 2026 sales grew 10% organically, with 7% from price and 3% from units. Gross Margin: Q2 2026 gross margin was 72.1%, a 210 basis point increase year-over-year. Operating Income: Recorded at $20.4 million, up 26%, resulting …

iMDx to Release Second Quarter Results on August 10, 2026

Insight Molecular Diagnostics Inc. (iMDx) announced it will release its second-quarter 2026 financial results after market close on August 10, 2026, followed by a live Zoom webinar for discussion. Additionally, iMDx's CEO and CFO will participate in the 11th Annual Needham Virtual MedTech & …

Lazard Asset Management LLC Buys Shares of 124,353 Hercules Capital, Inc. $HTGC

Lazard Asset Management LLC has acquired 124,353 shares of Hercules Capital, Inc. (HTGC) worth approximately $1.84 million, representing 0.07% of the company's stock. Hercules Capital, a specialty finance company, exceeded its quarterly EPS estimates and increased its quarterly dividend to $0.40 per share, resulting …

Ken Fisher's 4D Molecular Therapeutics Inc(FDMT) Holding History

This article details Ken Fisher's investment in 4D Molecular Therapeutics Inc (FDMT), held through Fisher Asset Management, LLC. As of June 30, 2026, he owns 65,751 shares valued at $874,490, representing 0% of his portfolio. Fisher has made one purchase of FDMT at an …

Form 144 4D Molecular Therapeutics For: 4 August By Investing.com

This article from Investing.com announces a Form 144 filing for 4D Molecular Therapeutics (FDMT) on August 4th. The content is brief, primarily serving as a placeholder for the filing information and is surrounded by typical financial news website navigation and market data. The article …

4D Molecular Therapeutics (FDMT) Insider David Kirn Sells 12,415 Shares

David Kirn, an insider at 4D Molecular Therapeutics (FDMT), sold 12,415 shares, bringing his total sales over the past year to 187,416 shares with no purchases. This selling activity, coupled with a lack of insider buying and a significant discount to the GuruFocus Value, …

LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates

LeMaitre Vascular (LMAT) reported Q2 earnings of $0.74 per share, falling short of the Zacks Consensus Estimate of $0.81, though it was an increase from $0.60 a year ago. The company's revenues of $70.38 million also missed expectations, despite being higher than the $64.23 …

LeMaitre Vascular (NASDAQ:LMAT) Issues Q3 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) has lowered its third-quarter 2026 earnings guidance, projecting EPS of $0.660–$0.710 and revenue of $66.3–$68.3 million, both below analyst consensus. The company also updated its full-year 2026 EPS guidance to $2.840–$2.940. Despite the lowered outlook, analyst sentiment remains "Moderate Buy" with …

FDMT (FDMT) insider plans 26,842-share Class A sale after sizable prior trades

An insider at 4D Molecular Therapeutics, Inc. (FDMT) plans to sell 26,842 Class A shares, valued at approximately $275,398.92, through Goldman Sachs & Co. LLC on or about August 4, 2026. These shares were originally acquired in a private transaction on December 15, 2020. …

How Investors Are Reacting To LeMaitre Vascular (LMAT) Slower Projected Revenue Growth And Mixed Earnings Track Record